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Oncogenic signaling in cancer cells alters glucose uptake and
utilization to supply sufficient energy and biosynthetic interme-
diates for survival and sustained proliferation. Oncogenic sig-
naling also prevents oxidative stress and cell death caused by
increased production of reactive oxygen species. However, ele-
vated glucose metabolism in cancer cells, especially in glioblas-
toma, results in the cells becoming sensitive to glucose depriva-
tion (i.e. in high glucose dependence), which rapidly induces cell
death. However, the precisemechanism of this type of cell death
remains unknown. Here, we report that glucose deprivation
alone does not trigger glioblastoma cell death. We found that,
for cell death to occur in glucose-deprived glioblastoma cells,
cystine and glutamine also need to be present in culture media.
We observed that cystine uptake through the cystine/glutamate
antiporter xCT under glucose deprivation rapidly induces
NADPH depletion, reactive oxygen species accumulation, and
cell death. We conclude that although cystine uptake is crucial
for production of antioxidant glutathione in cancer cells its
transport through xCT also induces oxidative stress and cell
death in glucose-deprived glioblastoma cells. Combining inhib-
itors targeting cancer-specific glucose metabolism with cystine
and glutamine treatment may offer a therapeutic approach for
glioblastoma tumors exhibiting high xCT expression.
Cancer cells increase glucose uptake andmetabolism to sup-
port survival and sustained proliferation. Thus, transporters or
enzymes involved in altered glucose metabolism have been
considered as potential therapeutic targets formany cancers (1,
2). One consequence of elevated glucose metabolism in cancer
cells, especially in glioblastoma cells, is that they become sensi-
tive to glucose deprivation (glucose addiction). Glioblastoma is
the most aggressive malignant brain tumor in humans with
poor survival (3), and previous studies have demonstrated that
withdrawal of glucose from culture medium rapidly induces
cell death in multiple glioblastoma cell lines (4–6). Because
normal astrocytes are not sensitive to glucose deprivation, the
difference in glucose sensitivity may provide an effective ther-
apeutic approach for glioblastoma. Glucose deprivation-in-
duced rapid cell death requires increased reactive oxygen
species (ROS)2 levels in cells (5–8). However, the precisemech-
anism of this type of cell death remains unknown.
ROS are produced in all cells as a by-product of normal cel-
lular metabolism, and at low levels, ROS increase cell prolifer-
ation and survival. However, when ROS levels become exces-
sively high, they cause oxidative stress, leading to cell death (9,
10). In cancer cells, ROS are produced at high levels and con-
tribute to accelerating the accumulation of additional muta-
tions and amplifying the tumorigenic phenotype. Therefore,
cancer cells up-regulate antioxidant systems and reduceROS to
moderate levels to avoid harmful oxidative stress and cell death
(9, 10). Thus, elucidation of molecular mechanisms underlying
how ROS levels are tightly regulated in cancer cells provides
opportunities for novel therapies against cancer.
Cancer cells also exhibit altered amino acid uptake and utili-
zation, and therefore they often express high levels of cell sur-
face amino acid transporters. Among them, xCT (SLC7A11),
the light chain of the cystine/glutamate antiporter system xc,
is up-regulated in brains of patients with glioblastoma and in
glioblastoma cell lines, and its expression correlates with tumor
invasion and poor survival (11–17). The system xc is com-
posed of xCTand the heavy chain subunit 4F2 (4F2hc, SLC3A2)
that exchanges extracellular cystine for intracellular glutamate
at the plasma membrane. The substrate specificity and activity
of system xc depend on xCT, and increased expression of xCT
leads to enhanced activity of cystine/glutamate exchange. In
contrast, 4F2hc is known to form heterodimers with several
light chains of specific amino acid transporters including xCT,
leading to the surface expression of amino acid transporters
(18–20). Within the cells, the imported cystine is reduced to
cysteine, which is the rate-limiting amino acid for reduced glu-
tathione synthesis. Glutathione is one of the most important
antioxidants in many types of cancer including glioblastoma.
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Conversely, treatment with pharmacological inhibitors of xCT
or depletion of glutathione in several types of cancer cells trig-
gers iron-dependent nonapoptotic cell death termed ferropto-
sis (21–23). Thus, intracellular transport of cystine is important
to reduce elevated ROS levels and to avoid oxidative stress-
induced cell death in cancer cells. However, xCT has recently
been reported to have an opposite effect on cell viability during
glucose deprivation (24, 25). In this study, we show that, in
glioblastoma cells expressing high levels of xCT, intracellular
transport of cystine through xCT rapidly induces NADPH
depletion, ROS accumulation, and cell death.
Results
Cystine and glutamine are required for glucose deprivation-
induced cell death in glioblastoma cells
As reported previously (5), we used U251 glioblastoma cell
line to show that glucose deprivation from the medium rapidly
induced cell death: cells were detached from the substrate
within 24 h. Unexpectedly, when U251 cells were deprived of
both glucose and all amino acids in the medium, few cells were
detached from the substrate over 24 h (Fig. 1A). To quantify
U251 cell death, we measured lactate dehydrogenase (LDH)
release in the culture medium at 24 h after deprivation of glu-
cose or glucose and amino acids. Glucose deprivation signifi-
cantly increased cell death, whereas deprivation of both glucose
and amino acids did not (Fig. 1B).We next used essential amino
acid (EAA) solution (containing arginine, cystine, histidine, iso-
leucine, leucine, lysine, methionine, phenylalanine, threonine,
tryptophan, tyrosine, and valine) and nonessential amino acid
(NEAA) solution (containing alanine, asparagine, aspartic acid,
glutamic acid, glycine, proline, and serine) to examine whether
addition of amino acids restored glucose deprivation-induced
cell death. Addition of EAA solution, but not NEAA solution or
glutamine (glutamine is not included in NEAA solution used
here), in the glucose- and amino acid-freemedium restored cell
death but not completely, and the combination of glutamine
and EAA solution was sufficient to restore glucose deprivation-
induced cell death (Fig. 1, A and B), suggesting that an amino
acid(s) in EAAs and glutamine are required for glucose depri-
vation-induced cell death in U251 cells. Similar results were
obtained using a trypan blue exclusion assay (Fig. 1C). To deter-
mine which amino acid(s) in EAA solution was responsible for
the glucose deprivation-induced rapid cell death, glutamine
and each amino acid in the EAA solution were added in the
glucose- and amino acid-free medium, and cell death was ana-
lyzed by LDH release assay. We found that addition of cystine
with glutamine in the glucose- and amino acid-free medium
triggered cell death (Fig. 1D). Addition of cystine alone also
induced cell death, but the combination of cystine and gluta-
mine was required to induce cell death at levels comparable
with those induced by deprivation of glucose alone (Fig. 1E).
Addition of glucose in the glucose- and amino acid-free
medium completely inhibited cell death induced by cystine and
glutamine, suggesting that cystine and glutamine do not affect
cell viability in the presence of glucose.We used other glioblas-
toma cell lines to show that this is not limited to U251 cells.
Similar resultswere obtained inT98GandLN229 cells, but they
showed different responses to glutamine. In T98G cells, cell
death induced by cystine alone was very weak, and addition of
glutamine greatly promoted cystine-induced cell death in the
glucose- and amino acid-free medium, although glutamine
alone had little effect on cell viability (Fig. 1F). Conversely, the
level of glucose deprivation-induced cell death in LN229 cells
was low compared with those in U251 and T98G cells, and
addition of glutamine had little effect on cystine-induced cell
death (Fig. 1G). In contrast, A172 cells did not die without glu-
cose, and neither addition of cystine alone nor addition of a
combination of cystine and glutamine under glucose and amino
acid deprivation conditions induced cell death in A172 cells
within 24 h (Fig. 1H). These results suggest that cystine and
glutamine are required for glucose deprivation-induced cell
death in glioblastoma cells.
The cystine/glutamate antiporter xCT is involved in glucose
deprivation-induced cell death
Because xCT, a subunit of the cysteine/glutamate antiporter
system xc, is up-regulated in glioblastoma cell lines (12, 16,
17), we speculated that cystine uptake through xCT triggered
cell death during glucose deprivation. In U251 cells, the xCT
inhibitor sulfasalazine (SSZ) or a high concentration (10mM) of
glutamate, both of which inhibit xCT-mediated cystine uptake
(20, 26), blocked glucose deprivation-induced cell death (Fig.
2A). Similar results were obtained in T98G and LN229 cells
(Fig. 2B). To confirm the involvement of xCT in glucose depri-
vation-induced cell death, xCT activity was genetically sup-
pressed in U251 cells using single-guide RNAs (sgRNAs). We
could not obtain complete xCT knock-out cells: this might be
due to the fact that cells derived from xCT knock-out mice fail
to proliferate and finally die under normal culture conditions
(20, 27–29). However, glucose deprivation-induced cell death
was greatly inhibited in cells with reduced expression of xCT
using sgRNAs targeting different regions of SLC7A11 gene
(sgSLC7A11-1, -2, and -3; Fig. 2C). Like parental cells, control
sgRNA-expressing cells died in the glucose-free medium. We
also found that A172 cells, which were much less sensitive to
glucose depletion, expressed very low levels of xCT compared
with other glioblastoma cell lines (Fig. 2D). These results sug-
gest that xCT mediates glucose deprivation-induced cell death
in glioblastoma cells. It has been reported that normal astro-
cytes express less xCT than glioblastoma cells and are not sen-
sitive to glucose deprivation (5, 17). Consistent with these find-
ings, the expression level of xCT in normal astrocytes prepared
from rat cerebral cortex was very low compared with that of
U251 cells, and glucose deprivation from the medium or addi-
tion of cystine and glutamine in the glucose- and amino acid-
free medium had little effect on the viability of normal astro-
cytes within 24 h (Fig. 2E). Glutamine is transported into cells
and metabolized to glutamate, and cystine uptake by xCT is
coupled to the export of glutamate. Our results show that glu-
tamine promoted, rather than inhibited, cystine-induced cell
death (Fig. 1), suggesting that the uptake of cystine, rather than
depletion of intracellular glutamate, contributes to xCT-medi-
ated cell death under glucose deprivation conditions in glio-
blastoma cells. In addition, glutamine did not promote the
cystine-induced cell death when U251 cells were treated with bis-2-
Cystine-induced glioblastoma cell death
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Figure 1. Cystine and glutamine induce cell death during glucose deprivation. A and B, U251 cells were placed in glucose-free or glucose- and amino
acid-free mediumwith or without glucose (5 mM), EAA, or NEAA solutions for 24 h. Scale bar, 200m (A). Quantification of cell death was performed using an
LDH release assay. Cells treatedwith 0.1% Tween 20were used for calculating 100% cell death (B). C, quantification of cell deathwas performed using a trypan
blue exclusion assay.D–H, cells were placed in glucose-free or glucose- and amino acid-freemediumwith orwithout glucose, glutamine (2mM), or cystine (0.2
mM) for 24 h (D, E, G, and H) or 12 h (F). Quantification of cell death was performed using an LDH release assay. Error bars represent S.D. (n 3). ***, p 0.001,
calculated by one-way ANOVA with Tukey’s post hoc test. Glc, glucose; AA, amino acids.
Cystine-induced glioblastoma cell death
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(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide (BPTES), a
glutaminase inhibitor, although BPTES alone had a slight cyto-
toxic effect (Fig. 2F). This result also supports the idea that the
conversion of glutamine to glutamate drives xCT-mediated
cystine uptake and cell death.One of the important roles of xCT
is to supply cysteine necessary for glutathione synthesis (18–
Figure 2. Glucose deprivation-induced cell death involves xCT.A and B, cells were placed in glucose-freemediumwith orwithout glucose (5mM), SSZ (250
M), or glutamic acid (10mM) for 24 h. Quantification of cell deathwas performed using an LDH release assay. Error bars represent S.D. (n 3). **, p 0.01; ***,
p  0.001, calculated by one-way ANOVA with Tukey’s post hoc test. C, immunoblot analysis of U251 cells after CRISPR-based gene editing with SLC7A11
sgRNAs (sgSLC7A11) or sgCtrl. Quantification of cell death was performed 24 h after glucose deprivation using an LDH release assay. Error bars represent S.D.
(n 3). *, p 0.05; ***, p 0.001, calculated by one-way ANOVAwith Tukey’s post hoc test. D, immunoblot analysis of glioblastoma cell lines. E, immunoblot
analysis of U251 cells and rat astrocytes. Quantification of cell death was performed 24 h after glucose deprivation using an LDH release assay. Error bars
represent S.D. (n 3). *, p 0.05; ***, p 0.001, calculated by one-way ANOVA with Tukey’s post hoc test. F and G, cells were placed in glucose- and amino
acid-free medium with or without cystine (0.2 mM), glutamine (2 mM), glycine (0.4 mM), or BPTES (10 M) for 24 h. Quantification of cell death was performed
using an LDH release assay. Error bars represent S.D. (n 3). **, p 0.01; ***, p 0.001, calculated by one-way ANOVA with Tukey’s post hoc test. n.s., not
significant; Glc, glucose; AA, amino acids.
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20). Glutathione is synthesized from three amino acids, cys-
teine, glutamate, and glycine, but addition of glycine had little
effect on cystine- and glutamine-induced cell death (Fig. 2G).
Cystine uptake through xCT induces ROS accumulation and
cell death during glucose deprivation
We next examined the morphological changes of U251 cells
after addition of cystine and glutamine in the glucose- and
amino acid-free medium. Addition of cystine and glutamine
rapidly triggered the formation of blebbing-like structures on
the plasma membrane and shrinking of the cell size (Fig. 3A,
arrows indicate typical blebbing-like structures). These mor-
phological changes were not observed in the absence of cystine.
The level of cleaved poly(ADP-ribose) polymerase, an apopto-
sis marker, did not change after glucose deprivation from the
medium or addition of cystine and glutamine in the glucose-
and amino acid-free medium (Fig. 3B; staurosporine and
MG132, both of which induce apoptosis in glioblastoma cells
(30, 31), were used as positive controls). In addition, the caspase
inhibitor Z-VAD-fmk had no effect on glucose deprivation- or
cystine-induced cell death (Fig. 3C). In contrast, treatmentwith
a cell-permeable ROS scavenger, MnTMPyP, completely sup-
pressed glucose deprivation- or cystine-induced cell death (Fig.
3D). These results suggest that cystine induces ROS-dependent
nonapoptotic cell death during glucose deprivation. Flow cyto-
metric analysis of U251 cells loaded with the cell-permeable
fluorescent ROS probe 2,7-dichlorofluorescein diacetate
revealed that although glucose deprivation increased intracel-
lular ROS levels combined depletion of glucose and amino acids
did not (Fig. 3E). However, addition of cystine and glutamine in
the glucose- and amino acid-freemedium caused an increase in
intracellular ROS levels (Fig. 3F). Addition of glutamine alone
had little effect on ROS levels.We next used xCT-deficient cells
to investigate whether xCT is involved in the ROS accumula-
tion under glucose deprivation. Although glucose withdrawal
increased intracellular ROS levels in control sgRNA-expressing
cells, it caused a decrease, rather than an increase, in intracel-
lular ROS levels in xCT-deficient cells (Fig. 3G). Thus, xCT
promotes ROS accumulation under glucose deprivation condi-
tions in glioblastoma cells. Because ROS are produced bymito-
chondrial oxidative phosphorylation in most cancer cells (2,
32), glucose deprivation may decrease mitochondrial oxidative
metabolism and therefore reduce intracellular ROS generation,
although the exact reason for reduced ROS levels in glucose-
deprived xCT-deficient cells is unknown. In contrast, recent
studies have revealed nonapoptotic iron-dependent cell death,
termed ferroptosis, which is driven by accumulation of lipid-
based ROS (21–23). However, the iron chelator deferoxamine
or the lipophilic antioxidant Trolox had little effect on the cys-
tine-induced cell death (data not shown).
Cystine uptake through xCT promotes NADPH depletion
during glucose deprivation
It is known that glucose metabolism generates NADPH,
which is important for protection against oxidative stress in
cancer cells (32, 33). We found that although glucose depriva-
tion in U251 cells rapidly increased the intracellular NADP/
NADPH ratio combined depletion of glucose and amino acids
did not. However, addition of cystine in the glucose- and amino
acid-free medium increased the NADP/NADPH ratio at lev-
els comparable with those induced by deprivation of glucose
alone (Fig. 4A). Although glutamine neither promoted nor
inhibited the cystine-induced increase in the NADP/NADPH
ratio 2 h after changing the medium, it significantly promoted
NADPH depletion by 4 h (Fig. 4B). The cystine-induced
NADPH depletion was completely suppressed by addition of
glucose (Fig. 4C). Thus, although glucose is essential for the
maintenance of NADPH levels, glucose deprivation alone does
not induce NADPH depletion. Similar results were obtained in
T98G cells, but they responded more rapidly than U251 cells
(Fig. 4D). In addition, the increase in theNADP/NADPHratio
induced by cystine alone was very weak, and it was greatly pro-
moted by addition of glutamine. These results are consistent
with the results of cell death assays. In contrast, the intracellular
NADP/NADPH ratio in A172 cells was low even when they
were placed in glucose-free medium containing cystine and
glutamine (Fig. 4E). To investigate whether xCT is involved in
the glucose deprivation-induced NADPH depletion, we used
xCT inhibitors and xCT-deficient cells. We found that xCT
inhibitors SSZ and high concentration of glutamate or loss of
xCT expression significantly blocked glucose deprivation-in-
duced NADPH depletion (Fig. 4F). These results suggest that
cystine uptake through xCT triggers NADPH depletion under
glucose deprivation conditions.
Glutamine has opposite effects on xCT-mediated cell death
In glioblastoma cells, glutamine metabolism is important for
cell survival when glucose metabolism is impaired (34). Gluta-
mine is transported into cells and metabolized to glutamate,
which is then converted into -ketoglutarate, and a recent
study reported that dimethyl-ketoglutarate (dm-KG), a cell-
permeable form of -ketoglutarate, greatly improved cell
viability during glucose deprivation in cancer cells (24, 25).
Consistent with this, treatment with dm-KG inhibited cys-
tine-induced cell death in U251 cells, although glutamine had
the opposite effect on cell viability (Fig. 5A). Addition of
dm-KG also inhibited the cystine-induced NADPH depletion
during glucose deprivation (Fig. 5B). Because the promoting
effect of glutamine on the cystine-induced NADPH depletion
was observed at 4 h, but not 2 h, after glucose deprivation, we
investigated the effect of glutamine on the NADP/NADPH
ratio for a short period of time. At 1 h after glucose deprivation,
glutamine significantly inhibited the cystine-induced increase
in the NADP/NADPH ratio (Fig. 5C). This inhibitory effect of
glutamine was suppressed by epigallocatechin gallate (EGCG),
an inhibitor of glutamate dehydrogenase that catalyzes the con-
version of glutamate to -ketoglutarate (Fig. 5D). These results
suggest that glutamine is metabolized into -ketoglutarate to
inhibit theNADPHdepletion and cell death under glucose dep-
rivation conditions.
Discussion
The reprogrammed glucose metabolism in cancer cells is
required for their growth and survival. In particular, the pro-
duction of NADPH from glucose is important to reduce the
intracellular ROS levels, and therefore glucose deprivation can
Cystine-induced glioblastoma cell death
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lead to cell death in cancer cells compared with normal cells.
NADPH is utilized for H2O2 detoxification by the glutathione
system (glutathione, glutathione reductase, and glutathione
peroxidase) and the thioredoxin system (thioredoxin, thiore-
doxin reductase, and peroxiredoxins). However, the precise
mechanismbywhich glucose deprivation in cancer cells rapidly
induces cell death has remained elusive. In this study, we iden-
tified amino acids cystine and glutamine as key mediators for
Cystine-induced glioblastoma cell death
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glucose deprivation-induced cell death in glioblastoma cells,
andwe show that glucose deprivation alone does not trigger cell
death. In the absence of glucose, cystine uptake through the
cysteine/glutamateantiporterxCTtriggersdepletionofNADPHand
elevation of ROS levels, which eventually cause cell death. Thus,
in glioblastoma cells with high xCT activity, glucose metabo-
lism protects against oxidative stress and cell death induced by
cystine uptake through xCT.We also found that glutamine has
opposite effects on glioblastoma cell viability under glucose
deprivation conditions. Glutamine via glutamate is converted
to -ketoglutarate and produces NADPH, which results in the
suppression of ROS accumulation and cell death during glucose
deprivation. The generation of NADPH by glutamine may
involve the malic enzymes (35, 36). Conversely, glutamine
finally promotes xCT-mediated NADPH depletion and cell
death. Because xCT transports cystine into the cell in exchange
for glutamate, glutamine appears to be required to provide glu-
tamate for xCT-mediated cystine uptake within the cells (Fig.
5E).
Recent studies have reported that inhibition of xCT in cancer
cells improves cell viability after glucose deprivation by using
glutamine as a carbon source (24, 25). -Ketoglutarate is a tri-
carboxylic acid (TCA) cycle component, and the conversion of
glutamine to -ketoglutarate maintains the TCA cycle and cell
survival. Expression of high levels of xCT suppresses glutamate-
dependent processes by exporting glutamate and thus renders
cancer cells highly dependent on glucose. In addition, xCT also
contributes to glutamine anaplerosis (37). Our results suggest
that cystine uptake through xCT induces ROS accumulation in
glioblastoma cells. Because glutamate is utilized for synthesis of
Figure3.Cystineuptake throughxCTcausesaccumulationofROSunderglucosedeprivation.A, after themediumwas replacedwithglucose- andamino
acid-free medium containing glutamine (2 mM) or glutamine and cystine (0.2 mM), phase-contrast images of U251 cells were captured at the indicated times.
Scale bar, 20 m. B, immunoblot analysis of U251 cells after the medium was replaced with glucose-free or glucose- and amino acid-free medium with or
without glucose (5 mM), glutamine (2mM), cystine (0.2 mM), staurosporine (0.1M), or MG132 (10M) for 24 h. C andD, U251 cells were placed in glucose-free
or glucose- and amino acid-freemediumwith or without glucose (5mM), glutamine (2mM), cystine (0.2mM), Z-VAD-fmk (10M), orMnTMPyP (10M) for 24 h.
Quantification of cell death was performed using an LDH release assay. Error bars represent S.D. (n 3). ***, p 0.001, calculated by one-way ANOVA with
Tukey’s post hoc test. E–G, FACS analysis of ROS generation in U251 cells. Cells were placed in glucose-free or glucose- and amino acid-free medium with or
without glucose or cystine for 3 h.Dark traces, cells placed in themediumwith glucose (E andG) or in themediumwithout glucose and amino acids (F). Similar
results were obtained in three independent experiments. Glc, glucose; AA, amino acids; DCF-DA, 2,7-dichlorofluorescein diacetate.
Figure 4. Cystine uptake through xCT induces NADPH depletion during glucose deprivation. After the medium was replaced with glucose-free or
glucose- and amino acid-free medium containing glucose (5 mM), glutamine (2 mM), cystine (0.2 mM), SSZ (250M), or glutamic acid (10 mM) for 2 (A, C, E, and
F), 0.5 or 2 (D), or 4 h (B), the NADP/NADPH ratiowasmeasured. Error bars represent S.D. (n 3). *, p 0.05; **, p 0.01; ***, p 0.001, calculated by one-way
ANOVA with Tukey’s post hoc test. Glc, glucose; AA, amino acids.
Cystine-induced glioblastoma cell death
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the antioxidant glutathione, xCT-mediated ROS accumulation
may drive glutamine metabolism to glutathione synthesis, which
results in dysfunction of the TCA cycle. However, it remains
unclear how cystine causes NADPH depletion under glucose
deprivation. Intracellularly, cystine is reduced cysteine, and it
has been assumed that this reaction is mediated by glutathione
Figure 5. Glutamine and-ketoglutarate inhibit cystine-inducedNADPHdepletion. A, cells were placed in glucose- and amino acid-freemediumwith or
without glutamine (2 mM), cystine (0.2 mM), or dm-KG (4 mM) for 24 h. Quantification of cell death was performed using an LDH release assay. B–D, after the
mediumwas replaced with glucose- and amino acid-free medium containing glutamine (2 mM), cystine (0.2 mM), dm-KG (4 mM), or EGCG (20M) for 2 (B) or
1 h (C and D), the NADP/NADPH ratio was measured. Error bars represent S.D. (n 3). *, p 0.05; **, p 0.01; ***, p 0.001, calculated by one-way ANOVA
with Tukey’s post hoc test. E, model of xCT-mediated cell death under glucose deprivation conditions. Glc, glucose; AA, amino acids.
Cystine-induced glioblastoma cell death
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and/or thioredoxin reductase 1 (20, 38, 39), both of which
require NADPH for their activities. Because glucose is a major
source of NADPH, high NADPH consumption due to reduc-
tion of imported cystine may rapidly cause NADPH depletion
under glucose deprivation. Another possiblemechanism is that
glutamate export by xCT impairs the conversion of glutamine
to-ketoglutarate and-ketoglutarate-mediatedNADPHpro-
duction, leading toNADPHdepletion in the absence of glucose.
Further studies are required to elucidate how cystine uptake
induces ROS accumulation and influences glutamine metabo-
lism in cancer cells with high levels of xCT.
Because cancer cells exhibit higher levels of ROS thannormal
cells to facilitate their growth, they are more susceptible to oxi-
dative stress (40, 41). Cystine is mainly imported via system xc
in glioblastoma (15), and it is well known that under normal
glucose conditions cystine is immediately reduced to cysteine
within the cell and used for glutathione synthesis. Glutathione
is one of the most important antioxidants in cancer cells, and
therefore xCT is up-regulated under oxidative stress in various
cancer cell types including glioblastoma (11, 19, 20). Recent
studies have shown that treatmentwith pharmacological inhib-
itors of xCT or depletion of glutathione in several types of can-
cer cells results in iron-dependent accumulation of lipid ROS
and cell death, termed ferroptosis. Thus, it has been accepted
that xCT has a positive effect on cancer cell survival. Indeed,
glioblastoma cells often up-regulate xCT, and the expression
level of xCT is highly associated with tumor growth (11–17).
However, cystine uptake by xCT promotes oxidative stress and
eventually cell death under glucose deprivation conditions.
Glucose transporters or enzymes involved in reprogrammed
glucose metabolism have been considered as potential thera-
peutic targets for cancer (32). Therefore, the combination of
inhibitors targeting cancer-specific glucose metabolism and
amino acids cystine and glutamine could be an attractive ther-
apeutic approach for glioblastoma with high xCT expression.
Experimental procedures
Reagents and antibodies
Minimum essential medium essential amino acids solution
(50) was purchased from Wako Pure Chemical Industries.
Nonessential amino acids solution (100) and all amino acids
were purchased from Nacalai Tesque. The medium without
glucose and amino acids was prepared by dissolving 0.2 g of
CaCl2, 0.1 mg of Fe(NO3)39H2O, 97.67 mg of MgSO4, 0.4 g of
KCl, 3.7 g of NaHCO3, 6.4 g of NaCl, 0.109 g of NaH2PO4, and
10 ml of minimum essential medium vitamin solution (100)
liquid (Thermo Fisher Scientific) in 1 liter of water. Inhibitors
were used at the following concentrations: SSZ (Sigma-Al-
drich), 250 M, glutamic acid (Sigma-Aldrich), 10 mM, MnT-
MPyP (Merck), 10 M, staurosporine (Sigma-Aldrich), 0.1 M;
MG132 (Wako Pure Chemical Industries), 10 M; Z-VAD-fmk
(R&DSystems), 10M;Trolox (SantaCruz Biotechnology), 100
M; deferoxamine mesylate salt (Santa Cruz Biotechnology),
100 M; dm-KG (Sigma-Aldrich), 4 mM; EGCG (Sigma-Al-
drich), 20 M; and BPTES (Sigma-Aldrich), 10 M. Antibodies
against xCT/SLC7A11 (D2M7A) and poly(ADP-ribose) poly-
merase (Asp-214) (D64E10) were purchased from Cell Signal-
ing Technology. The -tubulin antibody was purchased from
Sigma-Aldrich. Secondary antibodies conjugated to horserad-
ish peroxidase were purchased from Dako.
Cell culture and transfection
U251 cells were obtained from European Collection of
Authenticated Cell Cultures (catalog number EC09063001).
A172 and T98G cells were provided by the RIKENBioResource
Center through the National Bio-Resource Project of the Min-
istry of Education, Culture, Sports, Science and Technology,
Japan (A172, catalog number RCB2530; T98G, catalog number
RCB1954). LN229 cells were obtained from ATCC (catalog
number CRL-2611). Cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM) containing 10% fetal bovine serum, 4
mM glutamine, 100 units/ml penicillin, and 0.1 mg/ml strepto-
mycin under humidified air containing 5% CO2 at 37 °C. Cells
were transfected with the indicated expression vectors using
Lipofectamine 2000 (Life Technologies). All cell lines were
tested and found to be negative forMycoplasma contamination
using the EZ-PCRMycoplasma Test kit (Biological Industries).
Primary rat astrocyteswere prepared frompostnatal day 2 rat
cerebral cortex. The cerebral cortex was dissected in ice-cold
Hanks’ balanced salt solution and incubated inHanks’ balanced
salt solution with 0.25% trypsin and 0.1% DNase for 15 min at
37 °C. After washing in DMEM, the astrocytes were grown in
DMEM containing 10% fetal bovine serum, 4 mM glutamine,
100 units/ml penicillin, and 0.1 mg/ml streptomycin under
humidified air containing 5% CO2 at 37 °C.
Generation of xCT-deficient U251 cells
To generate xCT knock-outU251 cells, we used theCRISPR/
Cas9-mediated homology-independent knock-in system (42).
sgRNAs targeting SLC7A11 sequences were cloned into the
tandem sgRNA expression vector peSpCAS9(1.1)-2xsgRNA
(Addgene plasmid 80768), which has a Cas9 with enhanced
specificity (eSpCas9) and tandem expression cassettes of
sgRNAs. The first sgRNA targets SLC7A11, and the second
sgRNA targets the donor vector pDonor-tBFP-NLS-Neo (Add-
gene plasmid 80766). The cleavage site of pDonor-tBFP-NLS-
Neo is located upstream of the cytomegalovirus promoter to
enable insertion of the sequence encoding blue fluorescent pro-
tein (tBFP) fused with a triplicated nuclear localization signal
(NLS). U251 cells were seeded in two 6-cm dishes (250,000
cells/dish). Twenty-four hours later, the cells were cotrans-
fected with peSpCAS9(1.1)-2xsgRNA containing sgRNA tar-
geting SLC7A11 and pDonor-tBFP-NLS-Neo. Two days after
transfection, the cells were collected and seeded in two 10-cm
dishes in medium containing 250 g/ml G418 (Wako) to elim-
inate untransfected cells. Ten days after selection, colonies
grown from single cells with nuclear tBFP fluorescence were
isolated. These clones were expanded and screened by immu-
noblotting with anti-xCT antibody.
The following primers were used to clone sgRNA into peSp-
CAS9(1.1)-2xsgRNA: sgSLC7A11-1F, caccaccatagtagggacaca
cgg; sgSLC7A11-1R, aaacccgtgtgtccctactatggt; sgSLC7A11-2F,
cacctgcagggaaatgttaacggg; sgSLC7A11-2R, aaaccccgttaacatttc
cctgca; sgSLC7A11-3F, caccccccgtgtgtccctacta; sgSLC7A11-
3R, aaactagtagggacacacgggg; sgCtrl-F, cacctgagcgacaacgagatc
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cag; and sgCtrl-R, aaacctggatctcgttgtcgctca. The control sgRNA
(sgCtrl) vector used in this study contains sgRNA targeting the
human scribble sequence we tried to use for another study,
but this sgRNA had no effect on scribble protein expression,
although cells with nuclear tBFP fluorescence were isolated.
sgSLC7A11-1 and -2 were designed using the online tool
CRISPOR (http://crispor.tefor.net/crispor.py)3 and Fusi/Do-
ench scores (43). sgSLC7A11-3 was designed based on a previ-
ous report (19).
Glucose and amino acid deprivation conditions and cell death
experiments
On the day before the experiment, cells (20,000 cells/well)
were seeded in a 48-well plate (Greiner Bio-One, catalog num-
ber 677180). On the day of the experiment, cells were rinsed
twicewith PBS, and themediumwas replacedwith glucose-free
or glucose- and amino acid-free medium containing 10% dia-
lyzed FBS (HyClone) for 24 h. Cell death wasmeasured by LDH
release assay or trypan blue exclusion assay. The LDH release
assaywas performed using anMTXLDHkit (Kyokuto Pharma-
ceutical Industrial) according to the manufacturer’s instruc-
tion. The optical density was measured at 595 nm using a
microplate reader (Tecan, GENious). The value of LDH release
after treatment with 0.1% Tween 20 was defined as 100% cell
death. Glucose and amino acids were used in themedium at the
following concentrations: glucose, 5mM; arginine-HCl, 0.4mM;
cystine-2HCl, 0.2 mM; histidine-HCl-H2O, 0.2 mM; isoleucine,
0.8 mM; leucine, 0.8 mM; lysine-HCl, 0.8 mM; methionine, 0.2
mM; phenylalanine, 0.4 mM; threonine, 0.8 mM; tryptophan,
0.08 mM; tyrosine-2Na-2H2O, 0.4 mM; valine, 0.8 mM; gluta-
mine, 2 mM; and glycine, 0.4 mM.
Measurement of intracellular ROS
On the day before the experiment, U251 cells (50,000 cells/
well) were seeded in a 24-well plate (Greiner Bio-One, catalog
number 662160). On the day of the experiment, cells were
rinsed twice with PBS, and the medium was replaced with glu-
cose-free or glucose- and amino acid-free medium with or
without 5 mM glucose or 0.2 mM cystine for 3 h. 2,7-Dichlo-
rofluorescein diacetate (10 M; Sigma-Aldrich) was added for
the last 30 min. The cells were washed with PBS and har-
vested by trypsinization. Then the cells were resuspended in
50 l of ice-cold PBS and analyzed using a flow cytometer
(FACSCalibur, BD Biosciences). Data were collected from
the FL1 channel. At least 30,000 cells were analyzed per
condition.
Immunoblotting
Cell lysates were separated by SDS-PAGE and electropho-
retically transferred onto a polyvinylidene difluoride mem-
brane (Millipore Corp.). The membrane was blocked with 3%
low-fat milk in Tris-buffered saline and then incubated with
primary antibodies diluted with 3% low-fat milk or Can Get
Signal (Toyobo). The primary antibodies were detected with
horseradish peroxidase-conjugated secondary antibodies and a
chemiluminescence detection kit (ECL Prime, GE Healthcare
or Chemi-Lumi One L, Nacalai Tesque). The signals were cap-
tured with the LAS-3000 image analysis system (Fujifilm).
NADPH assay
On the day before the experiment, cells (50,000 cells/well)
were seeded in a 24-well plate. On the day of the experiment,
cells were rinsed twice with PBS, and the mediumwas replaced
with glucose-free or glucose- and amino acid-freemediumwith
or without 5mM glucose or 0.2mM cystine and 2mM glutamine
for the indicated times. The intracellular levels of NADPH and
total NADP (NADPH  NADP) were measured using enzy-
matic cycling methods as described previously (32) with modi-
fications. Briefly, cells were lysed in 100 l of extraction buffer
(20 mM nicotinamide, 20 mM NaHCO3, and 100 mM Na2CO3)
and centrifuged. For NADPH extraction, 40 l of the superna-
tant was incubated at 60 °C for 30 min. The cell extract (5 l)
was added to a 96-well plate (Greiner Bio-One, catalog number
655180) containing 40l of NADP cycling buffer (100mMTris-
HCl, pH 8.0, 0.5mM thiazolyl blue, 2mMphenazine ethosulfate,
and 5mMEDTA) containing 0.325 unit of glucose-6-phosphate
dehydrogenase. After a 1-min incubation, 5l of 10mMglucose
6-phosphatewas added to themixture, and the change in absor-
bance at 595 nm was measured every 5 min for 30 min at room
temperature using a microplate reader. The NADP/NADPH
ratio was calculated as ([total NADP] [NADPH])/[NADPH].
Data analysis
Datawere analyzed using analysis of variance (ANOVA)with
Tukey honest significant difference post hoc test. p 0.05 was
considered significant. Statistical analyses were performed
using KaleidaGraph (Synergy Software).
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